Association of sTREM‐1 and Neutrophil-to-Lymphocyte Ratio as Prognostic Markers in COVID-19 Short- and Long-Term Mortality

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Uusküla A, Jürgenson T, Pisarev H, et al. Long-term mortality following SARS-CoV-2 infection: a national cohort study from Estonia. Lancet Region Health Europe. 2022;18:100394. doi:10.1016/j.lanepe.2022.100394
   PubMedGoogle Scholar
• Mainous AG, Rooks BJ, Wu V, Orlando FA. COVID-19 post-acute sequelae among adults: 12 month mortality risk. Front Med. 2021;8. doi:10.3389/fmed.2021.778434
   Web of Science ®Google Scholar
• Vlachogiannis NI, Baker KF, Georgiopoulos G, et al. Clinical frailty, and not features of acute infection, is associated with late mortality in COVID‐19: a retrospective cohort study. J Cachexia, Sarcopenia Muscle. 2022;13(3):1502–1513. doi:10.1002/jcsm.12966
   PubMed Web of Science ®Google Scholar
• Wang W, Wang CY, Wang SI, Wei JCC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi:10.1016/j.eclinm.2022.101619
   PubMedGoogle Scholar
• Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol. 2022;19(5):332–341. doi:10.1038/s41569-021-00631-3
   PubMed Web of Science ®Google Scholar
• Copur S, Berkkan M, Basile C, Tuttle K, Kanbay M. Post-acute COVID-19 syndrome and kidney diseases: what do we know? J Nephrol. 2022;35(3):795–805. doi:10.1007/s40620-022-01296-y
   PubMed Web of Science ®Google Scholar
• Oronsky B, Larson C, Hammond TC, et al. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2021;64(1):66–74. doi:10.1007/s12016-021-08848-3
   PubMed Web of Science ®Google Scholar
• Tahir Huyut M, Huyut Z, Ilkbahar F, Mertoğlu C. What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality? Int Immunopharmacol. 2022;105:108542. doi:10.1016/j.intimp.2022.108542
   PubMed Web of Science ®Google Scholar
• Zhang J, Cao Y, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients. Allergy. 2021;76(2):533–550. doi:10.1111/all.14496
   PubMed Web of Science ®Google Scholar
• Alkhatip AAAMM, Kamel MG, Hamza MK, et al. The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. Expert Rev Mol Diagn. 2021;21(5):505–514. doi:10.1080/14737159.2021.1915773
   PubMed Web of Science ®Google Scholar
• Parthasarathi A, Padukudru S, Arunachal S, et al. The role of neutrophil-to-lymphocyte ratio in risk stratification and prognostication of COVID-19: a systematic review and meta-analysis. Vaccines. 2022;10(8):1233. doi:10.3390/vaccines10081233
   Web of Science ®Google Scholar
• Jiang J, Liu R, Yu X, et al. The neutrophil-lymphocyte count ratio as a diagnostic marker for bacteraemia: a systematic review and meta-analysis. Am J Emerg Med. 2019;37(8):1482–1489. doi:10.1016/j.ajem.2018.10.057
   PubMed Web of Science ®Google Scholar
• Niu D, Huang Q, Yang F, et al. Serum biomarkers to differentiate gram-negative, gram-positive and fungal infection in febrile patients. J Med Microbiol. 2021;70(7). doi:10.1099/jmm.0.001360
   PubMed Web of Science ®Google Scholar
• Siskind S, Brenner M, Wang P. TREM-1 modulation strategies for sepsis. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.907387
   Web of Science ®Google Scholar
• Richard-Greenblatt M, Boillat-Blanco N, Zhong K, et al. Prognostic accuracy of soluble triggering receptor expressed on myeloid cells (sTREM-1)-based algorithms in febrile adults presenting to Tanzanian outpatient clinics. Clin Infect Dis. 2019. doi:10.1093/cid/ciz419
   Web of Science ®Google Scholar
• Su L, Liu D, Chai W, Liu D, Long Y. Role of sTREM-1 in predicting mortality of infection: a systematic review and meta-analysis. BMJ Open. 2016;6(5):e010314. doi:10.1136/bmjopen-2015-010314
   PubMed Web of Science ®Google Scholar
• Kouassi K, Gunasekar P, Agrawal D, Jadhav G. TREM-1; is it a pivotal target for cardiovascular diseases? J Cardiovasc Dev Dis. 2018;5(3):45. doi:10.3390/jcdd5030045
   PubMed Web of Science ®Google Scholar
• Tammaro A, Derive M, Gibot S, Leemans JC, Florquin S, Dessing MC. TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives. Pharmacol Ther. 2017;177:81–95. doi:10.1016/j.pharmthera.2017.02.043
   PubMed Web of Science ®Google Scholar
• de Nooijer AH, Grondman I, Lambden S, et al. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Biosci Rep. 2021;41(7). doi:10.1042/BSR20210940
   PubMed Web of Science ®Google Scholar
• de Sá Resende A, Matos de Oliveira YL, Rodrigues de Moura T, Martins-Filho PR. Potential role of triggering receptor expressed on myeloid cells-1 (TREM-1) in SARS-CoV-2 infection: first insights. EXCLI J. 2021;20:722–723. doi:10.17179/excli2021-3581
   PubMed Web of Science ®Google Scholar
• Van Singer M, Brahier T, Ngai M, et al. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. J Aller Clin Immunol. 2021;147(1):99–106.e4. doi:10.1016/j.jaci.2020.10.001
   PubMed Web of Science ®Google Scholar
• Ribeiro TFG, Rstom RA, Barbosa PNVP, et al. Tomographic score (RAD-Covid Score) to assess the clinical severity of the novel coronavirus infection. Braz J Infect Dis. 2021;25(4):101599. doi:10.1016/j.bjid.2021.101599
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Seifert B, Urban P, et al. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart. 2014;100(4):288–294. doi:10.1136/heartjnl-2013-304588
   PubMed Web of Science ®Google Scholar
• Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–146. doi:10.1038/s41579-022-00846-2
   PubMed Web of Science ®Google Scholar
• Rabaan AA, Al-Ahmed SH, Muhammad J, et al. Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines. 2021;9(5):436. doi:10.3390/vaccines9050436
   PubMed Web of Science ®Google Scholar
• Maamar M, Artime A, Pariente E, et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38(6):901–909. doi:10.1080/03007995.2022.2042991
   PubMed Web of Science ®Google Scholar
• Huyut MT, Huyut Z. Effect of ferritin, INR, and D-dimer immunological parameters levels as predictors of COVID-19 mortality: a strong prediction with the decision trees. Heliyon. 2023;9(3):e14015. doi:10.1016/j.heliyon.2023.e14015
   PubMed Web of Science ®Google Scholar
• Doykov I, Hällqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. ‘The long tail of Covid-19’ - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349. doi:10.12688/f1000research.27287.1
   PubMedGoogle Scholar
• Mainous AG, Rooks BJ, Orlando FA. The impact of initial COVID-19 episode inflammation among adults on mortality within 12 months post-hospital discharge. Front Med. 2022;9. doi:10.3389/fmed.2022.891375
   Web of Science ®Google Scholar
• Morrow AJ, Sykes R, McIntosh A, et al. A multisystem, cardio-renal investigation of post-COVID-19 illness. Nat Med. 2022;28(6):1303–1313. doi:10.1038/s41591-022-01837-9
   PubMed Web of Science ®Google Scholar
• Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi:10.1371/journal.pone.0240784
   PubMed Web of Science ®Google Scholar
• van den Borst B, Peters JB, Brink M, et al. Comprehensive Health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73(5):e1089–e1098. doi:10.1093/cid/ciaa1750
   PubMed Web of Science ®Google Scholar
• Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378–383. doi:10.1016/j.jinf.2021.01.004
   PubMed Web of Science ®Google Scholar
• de Oliveira YLM, de Sá Resende A, Martins-Filho PR, de Moura TR. Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies. Inflammopharmacology. 2022;30(3):1037–1045. doi:10.1007/s10787-022-00972-6
   PubMed Web of Science ®Google Scholar
• Owen AM, Luan L, Burelbach KR, et al. MyD88-dependent signaling drives toll-like receptor-induced trained immunity in macrophages. Front Immunol. 2022:13. doi:10.3389/fimmu.2022.1044662
   Google Scholar
• Adukpo S, Gyan BA, Ofori MF, Dodoo D, Velavan TP, Meyer CG. Triggering receptor expressed on myeloid cells 1 (TREM-1) and cytokine gene variants in complicated and uncomplicated malaria. Tropical Medicine and International Health. 2016;21(12):1592–1601. doi:10.1111/tmi.12787
   PubMed Web of Science ®Google Scholar
• Hommes TJ, Dessing MC, Veer C, et al. Role of triggering receptor expressed on myeloid cells-1/3 in Klebsiella -derived pneumosepsis. Am J Respir Cell Mol Biol. 2015;53(5):647–655. doi:10.1165/rcmb.2014-0485OC
   PubMed Web of Science ®Google Scholar
• de Oliveira Matos A, Dos Santos Dantas PH, Figueira Marques Silva-Sales M, Sales-Campos H. The role of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-bacterial infections. Crit Rev Microbiol. 2020;46(3):237–252. doi:10.1080/1040841X.2020.1751060
   PubMed Web of Science ®Google Scholar
• Dantas PHDS, Matos ADO, da Silva Filho E, Silva-Sales M, Sales-Campos H. Triggering receptor expressed on myeloid cells-1 (TREM-1) as a therapeutic target in infectious and noninfectious disease: a critical review. Int Rev Immunol. 2020;39(4):188–202. doi:10.1080/08830185.2020.1762597
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–268. doi:10.1016/S1473-3099(13)70001-X
   PubMed Web of Science ®Google Scholar
• da Silva-Neto PV, de Carvalho JCS, Pimentel VE, et al. sTREM-1 predicts disease severity and mortality in COVID-19 patients: involvement of peripheral blood leukocytes and MMP-8 activity. Viruses. 2021;13(12):2521. doi:10.3390/v13122521
   PubMed Web of Science ®Google Scholar
• Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17(5):581–588. doi:10.1038/nm.2354
   PubMed Web of Science ®Google Scholar
• Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7(12):1266–1273. doi:10.1038/ni1411
   PubMed Web of Science ®Google Scholar
• Wan EYF, Zhang R, Mathur S, et al. Post-acute sequelae of COVID-19 in older persons: multi-organ complications and mortality. J Travel Med. 2023;30(5). doi:10.1093/jtm/taad082
   PubMed Web of Science ®Google Scholar
• Noreen S, Maqbool I, Madni A. Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021;894:173854. doi:10.1016/j.ejphar.2021.173854
   PubMed Web of Science ®Google Scholar